The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth
- PMID: 16020666
- DOI: 10.1158/1535-7163.MCT-04-0345
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth
Abstract
E7389, which is in phase I and II clinical trials, is a synthetic macrocyclic ketone analogue of the marine sponge natural product halichondrin B. Whereas its mechanism of action has not been fully elucidated, its main target seems to be tubulin and/or the microtubules responsible for the construction and proper function of the mitotic spindle. Like most microtubule-targeted antitumor drugs, it inhibits tumor cell proliferation in association with G(2)-M arrest. It binds to tubulin and inhibits microtubule polymerization. We examined the mechanism of action of E7389 with purified microtubules and in living cells and found that, unlike antimitotic drugs including vinblastine and paclitaxel that suppress both the shortening and growth phases of microtubule dynamic instability, E7389 seems to work by an end-poisoning mechanism that results predominantly in inhibition of microtubule growth, but not shortening, in association with sequestration of tubulin into aggregates. In living MCF7 cells at the concentration that half-maximally blocked cell proliferation and mitosis (1 nmol/L), E7389 did not affect the shortening events of microtubule dynamic instability nor the catastrophe or rescue frequencies, but it significantly suppressed the rate and extent of microtubule growth. Vinblastine, but not E7389, inhibited the dilution-induced microtubule disassembly rate. The results suggest that, at its lowest effective concentrations, E7389 may suppress mitosis by directly binding to microtubule ends as unliganded E7389 or by competition of E7389-induced tubulin aggregates with unliganded soluble tubulin for addition to growing microtubule ends. The result is formation of abnormal mitotic spindles that cannot pass the metaphase/anaphase checkpoint.
Similar articles
-
2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules.Mol Cancer Ther. 2006 Sep;5(9):2225-33. doi: 10.1158/1535-7163.MCT-06-0113. Mol Cancer Ther. 2006. PMID: 16985056
-
Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase.Mol Cancer Ther. 2008 Jul;7(7):2003-11. doi: 10.1158/1535-7163.MCT-08-0095. Mol Cancer Ther. 2008. PMID: 18645010 Free PMC article.
-
Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability.Biochemistry. 2010 Feb 16;49(6):1331-7. doi: 10.1021/bi901810u. Biochemistry. 2010. PMID: 20030375 Free PMC article.
-
Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators.Cell Struct Funct. 1999 Oct;24(5):329-35. doi: 10.1247/csf.24.329. Cell Struct Funct. 1999. PMID: 15216890 Review.
-
How do microtubule-targeted drugs work? An overview.Curr Cancer Drug Targets. 2007 Dec;7(8):730-42. doi: 10.2174/156800907783220417. Curr Cancer Drug Targets. 2007. PMID: 18220533 Review.
Cited by
-
Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.Breast Cancer Res Treat. 2021 Jul;188(1):117-131. doi: 10.1007/s10549-021-06184-w. Epub 2021 Mar 25. Breast Cancer Res Treat. 2021. PMID: 33763789 Free PMC article. Clinical Trial.
-
Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.Breast Cancer Res. 2022 Oct 28;24(1):71. doi: 10.1186/s13058-022-01560-w. Breast Cancer Res. 2022. PMID: 36307826 Free PMC article. Clinical Trial.
-
Eribulin as a Feasible and Safe Monotherapy in a Dialytic Pretreated Woman with Metastatic Breast Cancer: A Case Report.Oncology. 2018;94 Suppl 1(Suppl 1):16-18. doi: 10.1159/000489064. Epub 2018 Jul 23. Oncology. 2018. PMID: 30036877 Free PMC article.
-
Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience.Tumori. 2020 Aug;106(4):301-305. doi: 10.1177/0300891619887225. Epub 2019 Dec 18. Tumori. 2020. PMID: 31847742 Free PMC article.
-
A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer.Invest New Drugs. 2012 Jun;30(3):1203-7. doi: 10.1007/s10637-011-9673-x. Epub 2011 Apr 28. Invest New Drugs. 2012. PMID: 21526355 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources